tion methods respectively in all patients before and at frequent intervals after injection of Anistreplase or placebo. Patients were divided into reperfused (R) and non-reperfused (NR) groups 
Results
Equivocal ECG results were obtained in five patients because of either left ventricular hypertrophy or old myocardial infarction and they are considered separately later. Of the 17 patients remaining nine showed reperfusion (R) and eight did not (NR) on the basis of changes in the maximum ST segment elevation pre-dosing compared with 2 hours post dosing. Thus the R group showed a significant decrease in maximum ST segment elevation from 3-6 (2-8) pre-dosing to 1 1 (0-4) mm post dosing (69%; p < 001), whereas comparable changes for the NR group were an increase from 2-9 (2-5) to 4-1 (1-7) mm (44%; p < 0 05). ) comAge, height, weight, infarction site (anterior: n rank inferior ratio), male:female ratio, and time from outset of symptoms to dosing were comparable in the two groups ( suggests reduction in the size of the infarct in the former group. The significant positive correlation between TTP for myoglobin and AUC for CK and CKMB suggests that a shorter TTP myoglobin is associated with a decreased AUC and infarct size. Since the TTP for myoglobin in the R group is significantly less than the NR group this indicates that early reperfusion (resulting in a shorter TTP myoglobin) leads to a decreased AUC and size of infarct.
The Z ST elevation is also considered to be an index of infarct size.78 The ZST fell significantly (from pre-dosing values) at 2 hours post-dosing only in the R group, indicating a decreased infarct size in the R but not the NR group. However, since the number of patients receiving Anistreplase in the R and NR groups was equal (four) then the differing effects on TTP myoglobin, AUC, and infarct size in the two groups are unlikely to be due solely to the drug. The results of this preliminary study do not therefore explain the recent report of a significant (47%) reduction in 30 day mortality in double blind trials with Anistreplase.'°1
